Quality of Life and Adverse Effects in Epilepsy Patients (EPIKA)

Completed

• Conditions: Epilepsy

• Registration Number: NCT00302991
• Lead Sponsor: UCB Pharma

Brief Summary

Observational, multicentre, epidemiological study to determine the HRQOL of patients with epilepsy according to treatment sub-group and to validate the Spanish version of the Adverse Events Profile, produced by G. Baker et al. Three treatment groups will be examined: patients receiving only a new anti-epilepsy drug (AED), patients receiving a "classic" AED; patients receiving combination therapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-03
• Study First Submitted: 2006-03-13
• Study First Submitted QC: 2006-03-13
• Study First Posted: 2006-03-15
• Primary Completion: 2007-10
• Study Completion: 2007-10
• Status Verified: 2008-01
• Last Update Submitted: 2008-01-29
• Last Update Posted: 2008-01-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

• Epileptic adult patients treated at a stable dose with one or more AEDs for ≥ 3 months

Exclusion Criteria

• Symptomatic epilepsy due to malignant brain tumour or progressive brain disease.
• Confirmed diagnosis of a concomitant chronic disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified